Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed mixed results: improved GAAP net loss but negative adjusted EBITDA, and a cautious withdrawal of guidance. Positive factors include strategic cost reduction and potential CleanCap orders. However, the lack of concrete guidance and continued challenges in the discovery funding environment temper enthusiasm. The market response is likely to remain neutral as investors weigh restructuring benefits against ongoing uncertainties.
Key Financial Performance
Total Revenue $41.6 million, a decline from $69 million in Q3 2024. Excluding COVID GMP CleanCap, base revenue in Q3 2024 was $50.8 million, indicating an 18% decline year-over-year for the base business.
Biologic Safety Testing (BST) Revenue $16.3 million, growing at 7% year-over-year. Growth driven by demand for wholesale protein kits, quantification services, and MockV viral clearance products, with strength in U.S. and European markets.
Nucleic Acid Products (NAP) Revenue $25.4 million, declining 53% year-over-year. Base NAP business (excluding GMP COVID CleanCap) was down 29% year-over-year due to timing of GMP product orders, non-repeating CDMO builds, and macroeconomic impacts on discovery.
GAAP Net Loss $45.1 million for Q3 2025, compared to $172.5 million in Q3 2024. The prior year included a goodwill impairment charge of $154.2 million.
Adjusted EBITDA Negative $10.8 million for Q3 2025, compared to a positive $16.2 million in Q3 2024. Sequential improvement of more than $7 million expected in Q4.
Basic and Diluted EPS Loss of $0.18 per share in Q3 2025, compared to a loss of $0.68 per share in Q3 2024. Adjusted EPS was a loss of $0.08 in Q3 2025, compared to a loss of $0.01 in Q3 2024.
Cash and Long-term Debt $243.6 million in cash and $295.6 million in long-term debt as of Q3 2025.
Cash Used in Operations $15.2 million in Q3 2025, including a $1.6 million impact from restructuring expenses.
Stock-based Compensation $9.1 million in Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ModTail technology: Launched to enhance mRNA protein expression and duration, showing promising results in early trials. Aggressively driving adoption through targeted marketing and customer sampling. Expected to be a future revenue driver, especially in CAR-T and oncology applications.
IVT kits: Launched in May as an all-in-one solution for high-performance RNA synthesis. Consistent bookings growth month-over-month since launch. Serves as an entry point for customers to transition into using GMP products.
mRNA Builder platform: Launched as a computer-aided design and order platform for mRNA constructs. Early response encouraging with a doubling of orders placed and an 80% quote-to-order conversion rate.
Geographic performance: Strong performance in the U.S. and European markets for Biologics Safety Testing, with growth of 8% and 17% year-over-year, respectively. China market was down.
Customer engagement: Increased engagement from new and repeat customers in the cell and gene therapy market. Secured multiyear supply agreements, enhancing revenue visibility and strengthening long-term partnerships.
Cost structure realignment: Stabilized operations and significantly reduced expenses, with an expected annualized reduction of over $50 million. Sequential adjusted EBITDA improvement of more than $7 million expected in Q4.
Operational efficiency: Implemented changes in labor and overhead capitalization methodology, creating greater operational efficiency and long-term margin improvements.
Strategic realignment: Focused on operational excellence, revenue growth, and returning to positive adjusted EBITDA in 2026. Aligning investments with clear ROI and maintaining profitability improvement as a top priority.
Digital ecosystem expansion: Expanding the mRNA Builder platform for broader commercial launch, aiming to serve more clients with greater operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Decline in Nucleic Acid Products (NAP) Revenue: NAP revenue declined by 53% year-over-year in Q3 2025, driven by order timing in GMP and CDMO businesses, which are inherently variable. Base NAP business excluding COVID GMP CleanCap was down 29% year-over-year.
Impact of COVID GMP CleanCap Revenue Decline: COVID GMP CleanCap revenue, which was $66 million in 2024, is projected to drop to $10-$20 million annually starting in 2026, creating a significant revenue gap.
Discovery Market Challenges: The discovery market is impacted by broader macroeconomic conditions and lower funding levels, leading to reduced revenue from early-stage basic research.
Timing Variability in GMP Orders: GMP consumables revenue is highly variable and dependent on customer programs advancing into next-stage trials, leading to quarter-to-quarter revenue fluctuations.
CDMO Revenue Decline: CDMO revenue declined in Q3 2025 compared to Q3 2024 due to non-repeating builds from the prior year, though future growth is expected.
China Market Weakness: Revenue from the Chinese market declined in the Biologics Safety Testing (BST) segment, impacting overall performance.
Adjusted EBITDA Loss: The company reported an adjusted EBITDA loss of $10.8 million in Q3 2025, compared to a positive $16.2 million in Q3 2024, reflecting operational and financial challenges.
Cost Reduction and Restructuring Risks: While the company has reduced annualized expenses by over $50 million, the restructuring process carries execution risks and potential disruptions.
Macroeconomic and Funding Environment: Broader macroeconomic uncertainties and funding challenges continue to impact the discovery and preclinical development markets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Maravai anticipates closing 2025 with revenue of approximately $185 million, implying Q4 growth of 18% over Q3 and a 16% year-over-year growth in the base business excluding GMP COVID CleanCap.
Adjusted EBITDA Projections: The company expects a 2025 adjusted EBITDA loss of approximately $35 million, with a Q4 adjusted EBITDA loss of $3.5 million. Sequential adjusted EBITDA improvement of more than $7 million is expected in Q4.
Nucleic Acid Products (NAP) Segment: Strong sequential and year-over-year growth in base GMP consumables is expected in Q4. Annual revenues from COVID vaccines are projected to be $10 million to $20 million starting in 2026. The company anticipates an increase in the number of CDMO programs supported and average batch size per build in 2026.
Biologics Safety Testing (BST) Segment: Continued growth is expected, driven by strong recurring revenue and expanding full-service offerings. The company plans to fuel growth through novel mass spectrometry-based assays and robust demand for contract services and viral clearance kits.
Innovation and Product Launches: The ModTail technology, launched to enhance mRNA protein expression, is expected to drive future revenue, particularly in CAR-T and oncology applications. Additional IVT kits are planned for launch in 2026, building on the success of the initial kits launched in May 2025. The mRNA Builder platform is set for broader commercial launch, aiming to increase operational efficiency and customer engagement.
Cost Structure and Financial Discipline: Maravai is on track to lower annualized expenses by over $50 million, with more than $10 million in reductions achieved in the second half of 2025. The company is prioritizing cash generation and aligning investments with clear ROI to maintain profitability improvement as a top priority.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the anticipated revenue contribution from CleanCap in 2026, and do you have commitments for those orders?
A:The anticipated revenue contribution from CleanCap in 2026 is $10 million to $20 million. This is a combination of orders in hand and customer discussions.
Q:What is the split of cost savings in the fourth quarter and next year, and where are they coming from?
A:The $50 million plus cost savings are expected to come from labor cost reductions (40%-50%), facilities (15%-20%), CapEx (15%-20%), and other controllable spend (15%-20%). The split between COGS and OpEx is roughly 50-50.
Q:What were the key findings from the strategic review, and what is the visibility into achieving adjusted EBITDA and free cash flow positive targets for 2026?
A:The company was previously structured too heavily for its base, and restructuring has improved operations with minimal business impact. The leadership team is focused on building the business, and the targets for 2026 remain intact with optimism about achieving them.
Q:What is driving the BST performance and regional strengths?
A:BST performance has returned to growth for two consecutive quarters, driven by improving biotech funding. Strength is seen in the U.S. and Europe, while China remains weak. There is optimism about continued improvement.
Q:How should we think about gross margin expansion in Q4 and into 2026, especially with the contribution from COVID CleanCap?
A:Gross margin is expected to improve in Q4 due to cost reductions and product mix, particularly with more GMP orders. Specific guidance will be provided in the fourth quarter call.
Q:Is the $10 million to $20 million of COVID CleanCap orders mentioned last quarter the same as this quarter?
A:Yes, it is the same.
Q:What is contributing to the sequential improvement in the TriLink funnel and order velocity?
A:The improvement is due to typical order timing and lumpiness, as well as incremental larger orders tied to screening activities and earlier-stage clinical trials.
Q:What is the current state of the discovery funding environment?
A:The discovery funding environment is becoming more neutral but remains challenging. Orders over $25,000 (60% of revenues) are performing well, while orders under $25,000 (primarily academic and less than 4% of revenues) are still tough.
Q:What is the confidence level in ex-COVID GMP CleanCap for Q4 and 2026?
A:There is high confidence in Q4 as most orders are in hand, and October was strong. For 2026, visibility is good with binding purchase commitments and multiyear supply agreements.
Q:Are there any geographical differences in visibility for ex-COVID GMP CleanCap?
A:The company is seeing good strength outside the U.S. but did not provide specific geographical guidance.
Q:What is the long-term normalized growth rate for the Nucleic Acid segment?
A:The company expects growth in line with market peers, with potential upside from mRNA clinical trials. However, quantifying an exact number is difficult at this stage.
Q:What is the durability and visibility of Cygnus growth, and what is the potential for MockV and the viral clearance market?
A:Cygnus growth is holding strong, with protein kits growing at 7% and MockV growing rapidly due to industry adoption. The viral clearance market shows good traction, and APAC growth was 18% year-over-year, excluding China, which was down 12%.
Q:What is the pipeline of innovation, and can new products move the needle for growth?
A:The company is focused on differentiating products like ModTail and the IVT kit, which expand the customer base and improve mRNA processes. The pipeline includes consumables for GMP manufacturing, with potential high-growth products like ModTail.
Q:Review of Unclear Management Responses
A:Management avoided providing specific geographical guidance for ex-COVID GMP CleanCap visibility and did not quantify a long-term normalized growth rate for the Nucleic Acid segment, citing difficulty in making precise predictions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Acid Products
Americas Europe
BST strength
Builder response
CAR oncology
CDMO business
CDMO company
CDMO mRNA
CDMO service
CEO seat
CFO detail
COVID period
CleanCap GMP
CleanCap line
CleanCap sale
Cygnus position
Cygnus strength
Discovery momentum
GMP CleanCap
GMP consumables
Instructions
ModTail
Ms
Safety Testing
application
assay
cell gene
client
consumables GMP
core
cost structure
discovery stage
ecosystem
gene therapy
improvement
industry
launch
quote
timing
user
MRVI Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Unknown5-10
The earnings call reveals a decline in revenue, gross margin, and net income, coupled with increased operating expenses and reduced cash flow. These financial results are concerning, especially with management acknowledging potential risks and uncertainties. The lack of clarity in management's responses during the Q&A further exacerbates investor concerns. Despite the absence of strategic updates or shareholder return plans, the overall sentiment is negative due to the disappointing financial performance and risk factors.
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary presents a positive outlook for Maravai, with strong growth in GMP consumables, cost reductions, and AI-driven efficiency improvements. The Q&A section reinforces this with optimistic management sentiment, broad-based demand, and strong customer traction. Despite an adjusted EBITDA loss, the company's strategic focus on innovation and market expansion suggests potential for future profitability. The lack of negative guidance and anticipated revenue growth further support a positive stock price movement prediction.
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call revealed mixed results: improved GAAP net loss but negative adjusted EBITDA, and a cautious withdrawal of guidance. Positive factors include strategic cost reduction and potential CleanCap orders. However, the lack of concrete guidance and continued challenges in the discovery funding environment temper enthusiasm. The market response is likely to remain neutral as investors weigh restructuring benefits against ongoing uncertainties.
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call summary and Q&A highlight strong revenue growth, successful acquisitions, and product launches, which are positively received. The guidance remains optimistic, despite a negative EBITDA outlook, with management focusing on strategic growth, especially in non-U.S. markets. The Q&A reveals positive sentiment towards market expansion and strategic partnerships, such as the one with Thermo Fisher. However, management's lack of quarterly guidance and the focus on cost reductions are slight concerns. Overall, the sentiment is positive, with the potential for stock price growth.
MRVI Slides
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts2026-02-25
Maravai Lifesciences Q3 2025 slides: Revenue misses amid restructuring progress2025-11-06
Maravai Q2 2025 slides: New leadership unveils $50M cost-cutting plan amid losses2025-08-11
Maravai Q1 2025 slides: Pipeline growth amid financial challenges2025-05-12
MRVI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
